2-[acetyl-[(2E)-3,7-dimethylocta-2,6-dienyl]amino]-3-sulfanylpropanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[acetyl-[(2E)-3,7-dimethylocta-2,6-dienyl]amino]-3-sulfanylpropanoic acid
• 化学式: C₁₅H₂₅NO₃S
• 分子量: 299.4
• InChiKey: AYTYCLFIIYFEIR-XYOKQWHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] S-FTA AND S-FTA ANALOGUES CAPABLE OF INHIBITING RETINOL-DEPENDENT RBP4-TTR INTERACTION FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION, STARGARDT DISEASE, AND OTHER RETINAL DISEASE CHARACTERIZED BY EXCESSIVE LIPOFUSCIN ACCUMULATION<br/>[FR] S-FTA ET ANALOGUES DE S-FTA POUVANT INHIBER L'INTERACTION DE RBP4-TTR DÉPENDANTE DU RÉTINOL POUR LE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE, DE LA MALADIE DE STARGARDT ET D'AUTRES MALADIES DE LA RÉTINE CARACTÉRISÉES PAR UNE ACCUMULATION EXCESSIVE DE LIPOFUSCINE
  申请人：UNIV COLUMBIA

  公开号：WO2013166040A1

  公开（公告）日：2013-11-07

  A method for treating a disease characterized, by excessive lipofuscin accumulation in the retina in a mammal afflicted therewith comprising administering to the mammal an effective amount of a compound having the structure (I), wherein X is O or S, or an ester or a pharmaceutically acceptable salt thereof.

  一种治疗哺乳动物视网膜中过度脂褐质积累所表现的疾病的方法，包括向哺乳动物施用化合物(I)的有效量，其中X为O或S，或其酯或药用可接受的盐。
• Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US11479802B2

  公开（公告）日：2022-10-25

  Screening methods as well as kits for identifying modulators of hydroxysteroid (17-beta) dehydrogenase (HSD17B) family member proteins, such as HSD17B13, are provided. The methods comprise screening molecules for their capacity to modulate the HSD17B family member protein, including inhibiting the HSD17B family member protein, as measured by substrate depletion, product concentration from the HSD17B family member protein substrate conversion or NADH concentration, levels of labeled substrate, luciferin light emission, or combinations thereof. Inhibitors of HSD17B family member proteins identified through the screening methods may be used to treat liver diseases, disorders, or conditions in which the HSD17B family member protein plays a role.

  本发明提供了用于鉴定羟基类固醇（17-beta）脱氢酶（HSD17B）家族成员蛋白（如 HSD17B13）调节剂的筛选方法和试剂盒。这些方法包括筛选分子，以确定其调节 HSD17B 家族成员蛋白的能力，包括抑制 HSD17B 家族成员蛋白的能力，通过底物耗竭、HSD17B 家族成员蛋白底物转化产物浓度或 NADH 浓度、标记底物水平、荧光素发光或其组合来测量。通过筛选方法鉴定的 HSD17B 家族成员蛋白的抑制剂可用于治疗 HSD17B 家族成员蛋白起作用的肝脏疾病、失调或病症。
• ASSAYS FOR SCREENING ACTIVITY OF MODULATORS OF MEMBERS OF THE HYDROXYSTEROID (17-BETA) DEHYDROGENASE (HSD17B) FAMILY
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：EP3610029A1

  公开（公告）日：2020-02-19
• Assays For Screening Activity Of Modulators Of Members Of The Hydroxysteroid (17-Beta) Dehydrogenase (HSD17B) Family
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US20180291422A1

  公开（公告）日：2018-10-11

  Screening methods as well as kits for identifying modulators of hydroxysteroid (17-beta) dehydrogenase (HSD17B) family member proteins, such as HSD17B13, are provided. The methods comprise screening molecules for their capacity to modulate the HSD17B family member protein, including inhibiting the HSD17B family member protein, as measured by substrate depletion, product concentration from the HSD17B family member protein substrate conversion or NADH concentration, levels of labeled substrate, luciferin light emission, or combinations thereof. Inhibitors of HSD17B family member proteins identified through the screening methods may be used to treat liver diseases, disorders, or conditions in which the HSD17B family member protein plays a role.
• [EN] ASSAYS FOR SCREENING ACTIVITY OF MODULATORS OF MEMBERS OF THE HYDROXYSTEROID (17-BETA) DEHYDROGENASE (HSD17B) FAMILY<br/>[FR] DOSAGE DE CRIBLAGE DE L'ACTIVITÉ DES MODULATEURS DE MEMBRES DE LA FAMILLE DES HYDROXYSTÉROÏDE (17-BÊTA) DÉSHYDROGÉNASE (HSD17B)
  申请人：REGENERON PHARMA

  公开号：WO2018190970A1

  公开（公告）日：2018-10-18

  Screening methods as well as kits for identifying modulators of hydroxysteroid (17-beta) dehydrogenase (HSD17B) family member proteins, such as HSD17B13, are provided. The methods comprise screening molecules for their capacity to modulate the HSD17B family member protein, including inhibiting the HSD17B family member protein, as measured by substrate depletion, product concentration from the HSD17B family member protein substrate conversion or NADH concentration, levels of labeled substrate, luciferin light emission, or combinations thereof. Inhibitors of HSD17B family member proteins identified through the screening methods may be used to treat liver diseases, disorders, or conditions in which the HSD17B family member protein plays a role.